Finerenone (formerly known as BAY94-8862; BAY-948862; Kerendia) is a potent, selective, and orally bioavailable non-steroidal anti-mineralocorticoid or mineralocorticoid receptor (MR) antagonist (IC50 = 18 nM) that was approved in July 2021 by the US FDA to reduce the risk of kidney and heart complications in chronic kidney disease associated with type 2 diabetes.

Apararenone (formerly known as MT-3995) is a novel, potent and selective non-steroidal mineralocorticoid/aldosterone receptor antagonist under development for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis.

Esaxerenone, formerly known as CS-3150, XL-550, is a nonsteroidal antimineralocorticoid which was discovered by Exelixis and is now under development by Daiichi Sankyo Company for the treatment of hypertension, essential hypertension, hyperaldosteronism, and diabetic nephropathies.

Fludrocortisone Acetate, the acetate form of the synthetic corticosteroid fludrocortisone, is a potent mineralocorticoid receptor agonist.

Osilodrostat (LCI699; LCI-699; Isturisa) is a novel and potent inhibitor of 11β-hydroxylase and approved medication for the treatment of adults with Cushing’s disease.

Eplerenone (also known as CGP 30083, Inspra, SC-66110) is a potent and selective mineralocorticoid receptor antagonist with an IC50 of 0.36 μM, it blocks the action of aldosterone, used to control high blood pressure.